ATP6V1A as a Radioligand Therapy Target
ATP6V1A, ATPase H+ transporting V1 subunit A, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ATP6V1A staining is highest in lymphoma (100% of samples positive), thyroid cancer (100% of samples positive) and glioma (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is ATP6V1A a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in lymphoma, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ATP6V1A expression in cancer
Protein expression of ATP6V1A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lymphoma | 0.94 | High | 100% |
| Thyroid Cancer | 0.92 | High | 100% |
| Glioma | 0.88 | High | 100% |
| Neuroendocrine Tumors | 0.83 | High | 100% |
| Colorectal Cancer | 0.79 | High | 100% |
| Lung Cancer | 0.70 | High | 100% |
| Ovarian Cancer | 0.70 | High | 100% |
| Melanoma | 0.70 | High | 100% |
| Bladder Cancer | 0.69 | High | 100% |
| Testicular Cancer | 0.67 | High | 100% |
| Breast Cancer | 0.64 | High | 100% |
| Endometrial Cancer | 0.64 | High | 100% |
| Skin Cancer | 0.63 | High | 100% |
| Prostate Cancer | 0.61 | High | 100% |
| Pancreatic Cancer | 0.59 | High | 100% |
| Head and Neck Cancer | 0.58 | High | 100% |
| Kidney Cancer | 0.58 | High | 92% |
| Gastric Cancer | 0.58 | High | 100% |
| Cervical Cancer | 0.56 | High | 100% |
| Liver Cancer | 0.41 | Medium | 78% |
Is ATP6V1A internalized?
Nuclens has not yet extracted internalization evidence for ATP6V1A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
ATP6V1A clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for ATP6V1A yet. Search ClinicalTrials.gov for ATP6V1A trials.
ATP6V1A normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ATP6V1A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ATP6V1A gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -1.98 (essential, below −0.5). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lymphoma radioligand targets
c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD45 (PTPRC) · CD19 · SSTR2 · STEAP2 · CD22
See all radioligand therapy targets in lymphoma.
See how ATP6V1A ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.